Filed pursuant to 424(b)(3)

Registration No. 333-213051

PROSPECTUS SUPPLEMENT

(To Prospectus dated February 3, 2017)

 

 

BIONIK LABORATORIES CORP.

 

11,352,675 Shares of Common Stock

 

This prospectus supplement (the “Prospectus Supplement”) supplements our prospectus dated February 3, 2017 (the “Prospectus”), relating to the resale of up to an aggregate of 11,352,675 shares of our common stock, par value $0.001 per share, by the selling stockholders identified in the Prospectus. Of such shares, 1,579,516 shares may be issued upon exercise of warrants held by the selling stockholders. We are not offering any shares of common stock for sale under the prospectus or this Prospectus Supplement and we will not receive any proceeds from sales of shares of our common stock by the selling stockholders; however, we will receive a total of approximately $1,064,385 if all the warrants are exercised in full.

 

Recent Developments

 

This Prospectus Supplement is being filed to update and supplement the information in the Prospectus with the information contained in our Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2016, filed with the Securities and Exchange Commission on February 14, 2017 (the “10-Q”). Accordingly, we have attached the 10-Q to this Prospectus Supplement. Any statement contained in the Prospectus shall be deemed to be modified or superseded to the extent that information in this Prospectus Supplement modifies or supersedes such statement. Any statement that is modified or superseded shall not be deemed to constitute a part of the Prospectus except as modified or superseded by this Prospectus Supplement.

 

This Prospectus Supplement should be read in conjunction with, and may not be delivered or utilized without, the Prospectus.

 

Investing in our common stock involves significant risks. You should read the section entitled “Risk Factors” beginning on page 5 of the Prospectus for a discussion of certain risk factors that you should consider before investing in our common stock.

 

Neither the Securities and Exchange Commission nor any state securities commission or other regulatory body has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

 

This Prospectus Supplement does not constitute an offer to sell or the solicitation of an offer to buy any securities.

 

The date of this Prospectus Supplement is February 14, 2017

 

 

 

 

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

 

FORM 10-Q

 

xQuarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
for the Quarterly Period Ended December 31, 2016

 

-OR-

 

¨Transition Report Pursuant to Section 13 or 15(d) of the Securities And Exchange Act of 1934
for the transition period from _______ to _______

 

Commission File Number: 000-54717

 

BIONIK LABORATORIES CORP.

 

(Exact name of Registrant in its charter)

 

Delaware   27-1340346
(State or Other Jurisdiction of
Incorporation or Organization)
  (I.R.S. Employer Identification  Number)

 

483 Bay Street, N105    
Toronto, Ontario   M5G 2C9
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (416) 640-7887

 

Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company as defined by Rule 12b-2 of the Exchange Act):

 

Large accelerated filer ¨ Non-accelerated filer ¨
Accelerated filer ¨ Smaller reporting company x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

 

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date. As of February 14, 2017, 47,242,709 shares of Common Stock, par value $0.001 per share.

 

 

 

 

BIONIK LABORATORIES CORP.

FORM 10-Q

 

INDEX

 

  Page
PART I – FINANCIAL  INFORMATION
   
Item 1. Financial Statements  
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 24
Item 3. Quantitative and Qualitative Disclosures About Market Risk 31
Item 4. Controls and Procedures 31
   
PART II - OTHER  INFORMATION
   
Item 1. Legal Proceedings 32
Item 1A. Risk Factors 32
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 32
Item 3. Defaults Upon Senior Securities 32
Item 4. Mine Safety Disclosures 32
Item 5. Other Information 32
Item 6. Exhibits 32
   
SIGNATURES 33

 

 2 

 

 

BIONIK LABORATORIES CORP.

 

UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

 

December 31, 2016 and 2015

 

(Amounts expressed in US Dollars)

Index

 

  Page
   
Unaudited Condensed Consolidated Interim Financial Statements 3
   
Condensed Consolidated Interim Balance Sheets as at December 31, 2016 (Unaudited) and March 31, 2016 (Audited) 4
   
Condensed Consolidated Interim Statements of Operations and Comprehensive Income (Loss) (Unaudited) for the three and nine month periods December 31, 2016 and 2015 5
   
Condensed Consolidated Interim Statements of Changes in Shareholders’ Equity (Deficiency) (Unaudited) for the nine month periods ended December 31, 2016 and 2015 6
   
Condensed Consolidated Interim Statements of Cash Flows (Unaudited) for the nine month periods ended December 31, 2016 and 2015 7
   
Notes to Condensed Consolidated Interim Financial Statements (Unaudited) 8-23

 

 3 

 

 

Bionik Laboratories Corp.

Condensed Consolidated Interim Balance Sheets

(Amounts expressed in U.S. Dollars)

 

  

As at
Dec. 31, 2016

(Unaudited)

  

As at
March 31, 2016

(Audited)

 
   $   $ 
Assets          
Current          
Cash and cash equivalents   580,952    5,381,757 
Accounts receivable   253,849    - 
Prepaid expenses and other receivables (Note 4)   153,010    231,733 
Inventories (Note 5)   194,573    - 
Due from related parties (Note 8(a))   40,913    41,445 
Short term advances   -    125,153 
Loan receivable   -    379,908 
Total Current Assets   1,223,297    6,159,996 
Equipment (Note 6)   203,745    76,750 
Intangible assets and goodwill (Note 3)   27,888,979    - 
Total Assets   29,316,021    6,236,746 
           
Liabilities and Shareholders’ Deficiency          
Current          
Accounts payable (Notes 8(b) and 13)   405,315    320,871 
Accrued liabilities (Notes 8(b) and 7)   738,863    515,979 
Current portion of lease payable (Note 6)   4,603    - 
Promissory notes payable (Note 7)   231,781    - 
Convertible loans (Note 7)   483,333    - 
Customer deposits   114,487    - 
Deferred revenue   97,165    - 
Warrant derivative liability (Note 11)   2,582,040    5,135,990 
    4,657,587    5,972,840 
           
Demand notes payable (Note 7)   328,361    - 
Lease payable (Note 6)   15,729    - 
Total Liabilities   5,001,677    5,972,840 
Shareholders’ Equity          
Preferred Stock, par value $0.001; Authorized 9,999,999 (March 31, 2016 – 9,999,999) Issued and outstanding - nil (March 31, 2016 – nil)   -    - 
Special Voting Preferred Stock, par value $0.001; Authorized, issued and outstanding – 1 (March 31, 2016 – 1)   -    - 
Common Stock, par value $0.001; Authorized - 150,000,000 (March 31, 2016 – 150,000,000); Issued and outstanding – 46,362,541 and 50,000,000 Exchangeable Shares (March 31, 2016 – 22,591,292 and 50,000,000 Exchangeable Shares) (Note 9)   96,362    72,591 
Additional paid in capital   38,232,457    11,801,146 
Deficit   (14,056,624)   (11,651,980)
Accumulated other comprehensive income   42,149    42,149 
Total Shareholders’ Equity   24,314,344    263,906 
Total Liabilities and Shareholders’ Equity   29,316,021    6,236,746 

 

Going Concern (Note 1)

Commitments and Contingencies (Note 14)

 

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

 

 4 

 

 

Bionik Laboratories Corp.

Condensed Consolidated Interim Statements of Operations and Comprehensive Income (Loss)

For the three and nine month periods ended December 31, 2016 and 2015 (unaudited)

(Amounts expressed in U.S. Dollars)

 

   Three
 months
 ended Dec.
31, 2016
   Nine
months
ended Dec.
31, 2016
   Three
months
ended Dec.
31, 2015
  

Nine

months
ended Dec.

31 2015

 
   $   $   $   $ 
Sales   372,426    553,900    -    - 
Cost of Sales   334,786    405,680    -    - 
Gross Margin   37,640    148,220    -    - 
                     
Operating expenses                    
Sales and marketing   377,046    646,509    -    - 
Research and development   571,671    1,803,234    593,686    1,971,809 
General and administrative   409,669    2,291,136    438,628    1,313,071 
Share-based compensation expense (Notes 9(v) and 10)   227,540    651,630    13,291    1,337,573 
Depreciation (Note 6)   24,028    57,781    20,877    53,357 
Total operating expenses   1,609,954    5,450,290    1,066,482    4,675,810 
                     
Other expenses (income)                    
Interest expense (Note 7)   13,808    23,839    -    - 
Other income   (4,363)   (410,877)   (5,566)   (28,578)
Foreign exchange loss   -    -    184,125    184,125 
Change in fair value of warrant derivative liability (Note 11)   (771,341)   (2,510,388)   (2,457,778)   (6,871,597)
                     
Total other expenses (income)   (761,896)   (2,897,426)   (2,279,219)   (6,716,050)
                     
Net income (loss) and comprehensive income (loss) for the period   (810,418)   (2,404,644)   1,212,737    2,040,240 
                     
Income (loss) per share – basic  $(0.01)  $(0.03)  $0.02   $0.03 
Income (loss) per share – diluted  $(0.01)  $(0.03)  $0.02   $0.03 
                     
Weighted average number of shares outstanding – basic   96,362,541    90,286,864    72,412,532    67,210,266 
                     
Weighted average number of shares outstanding – diluted   93,043,498    94,320,801    72,412,532    67,210,266 

 

The accompanying notes are an integral part of these condensed consolidated interim financial statements

 

 5 

 

 

Bionik Laboratories Corp.

Condensed Consolidated Interim Statements of Changes in Shareholders’ Equity (Deficiency)

for the nine month periods ended December 31, 2016 and 2015 (unaudited)

(Amounts expressed in US Dollars)

 

  

Special voting

preferred shares

   Common Shares                     
  

Shares

 

   Amount
 $
  

Shares

 

   Amount
  $
  

Additional
Paid in
Capital

$

   Shares to be
Issued
$
  

Deficit

$

  

Accumulated
Other
Comprehensive
Income

$

  

Total

$

 
Balance, March 31, 2015   1         65,839,563    65,840    10,081,394    -    (12,688,128)   42,149    (2,498,745)
Shares issued on private placement                                             
(Notes 9(i),(ii) and (iii))   -    -    6,568,750    6,568    (6,568)   -    -    -    - 
Shares to be issued for services   -    -    -    -    -    98,900    -    -    98,900 
Share compensation expense   -    -    20,000    20    1,337,573    -    -    -    1,337,593 
Net income for the period   -    -    -    -    -    -    2,040,240    -    2,040,240 
Balance, December 31, 2015   1    -    72,428,313    72,428    11,412,399    98,900    (10,647,888)   42,149    977,988 
                                              
Shares issued for services   -    -    117,471    117    169,583    (98,900)   -    -    70,800 
Cashless exercise of warrants   -    -    45,508    46    60,920    -    -    -    60,966 
Share compensation expense   -    -    -    -    158,244    -    -    -    158,244 
Net income for the period   -    -    -    -    -    -    (1,004,092)   -    (1,004,092)
Balance, March 31, 2016   1    -    72,591,292    72,591    11,801,146    -    (11,651,980)   42,149    263,906 
                                              
Shares issued on Acquisition (Note 3)   -    -    23,650,000    23,650    23,153,350    -    -    -    23,177,000 
Stock compensation expense – vested                                             
options on Acquisition (Note 3)   -    -    -    -    2,582,890    -    -    -    2,582,890 
Cashless exercise of warrants   -    -    51,249    51    43,511    -    -    -    43,562 
Shares issued for services (Note 9(v))   -    -    70,000    70    59,430    -    -    -    59,500 
Share compensation expense                                             
(Note 10)   -    -    -    -    592,130    -    -    -    592,130 
Net loss for the period   -         -    -    -    -    (2,404,644)   -    (2,404,644)
Balance, December 31, 2016   1    -    96,362,541    96,362    38,232,457    -    (14,056,624)   42,149    24,314,344 

 

The accompanying notes are an integral part of these condensed consolidated interim financial statements

 

 6 

 

 

Bionik Laboratories Corp.

Condensed Consolidated Interim Statements of Cash Flows

for the nine month periods ended December 31, 2016 and 2015 (unaudited)

(Amounts expressed in US dollars)

 

   Nine months ended
Dec. 31, 2016
   Nine months ended
Dec. 31, 2015
 
   $   $ 
Operating activities          
Net (loss) income for the period   (2,404,644)   2,040,240 
Adjustment for items not affecting cash          
Depreciation   57,781    53,357 
Interest expense   23,839    - 
Share- based compensation expense   592,130    1,337,573 
Shares issued for services   59,500    98,900 
Change in fair value of warrant derivative liability   (2,510,388)   (6,871,597)
    (4,181,782)   (3,341,527)
Changes in non-cash working capital items          
Accounts receivable   (247,359)   - 
Prepaid expenses and other receivables   95,562    (29,798)
Due from related parties   532    2,926 
Inventories   (120,894)   (74,069)
Accounts payable   (718,270)   (275,106)
Accrued liabilities   (492,047)   - 
Customer deposits   28,000    - 
Lease payable   (2,303)   - 
Deferred revenue   97,615    - 
Net cash used in operating activities   (5,540,946)   (3,717,574)
Investing activities          
Acquisition of equipment   (9,827)   (39,811)
Provision of a loan receivable   -    (307,459)
Net cash used in investing activity   (9,827)   (347,270)
Financing activity          
Proceeds from issuance of shares, net of issue costs   -    4,556,818 
Provision of convertible loans   483,333    - 
Cash acquired on acquisition   266,635    - 
Net cash provided by financing activity   749,968    4,556,818 
           
Net (decrease) increase in cash and cash equivalents for the period   (4,800,805)   491,974 
Cash and cash equivalents, beginning of period   5,381,757    6,125,108 
Cash and cash equivalents, end of period   580,952    6,617,082 
           
Supplemental information:          
Assets acquired and liabilities assumed:          
Current assets, including cash acquired of $266,635  $478,843      
Equipment   59,749      
Intangible assets and goodwill   27,888,979      
Accounts payable   (241,299)     
Accrued liabilities   (361,029)     
Customer deposits   (86,487)     
Demand notes payable   (324,894)     
Promissory notes payable   (217,808)     
Bionik advance   (1,436,164)     
Non-cash consideration  $25,759,890      

 

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

 

 7 

 

 

BIONIK LABORATORIES CORP.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the nine month periods ended December 31, 2016 and 2015 (unaudited)

(Amounts expressed in U.S. Dollars)

 

1.NATURE OF OPERATIONS AND GOING CONCERN

 

The Company and its Operations

 

Bionik Laboratories Corp. (formerly Drywave Technologies Inc., the “Company” or “Bionik”) was incorporated on January 8, 2010 in the State of Colorado as Strategic Dental Management Corp. On July 16, 2013, the Company changed its name to Drywave Technologies Inc. (“Drywave”) and its state of incorporation from Colorado to Delaware. Effective February 13, 2015, the Company changed its name to Bionik Laboratories Corp. and reduced the authorized number of shares of common stock from 200,000,000 to 150,000,000. Concurrently, the Company implemented a 1-for-0.831105 reverse stock split of the common stock, which had previously been approved on September 24, 2014.

 

On February 26, 2015, the Company entered into a Share Exchange Agreement and related transactions whereby it acquired Bionik Laboratories Inc., a Canadian Corporation (“Bionik Canada”) and Bionik Canada issued 50,000,000 Exchangeable Shares, representing a 3.14 exchange ratio, for 100% of the then outstanding common shares of Bionik Canada (the “Merger”). The Exchangeable Shares are exchangeable at the option of the holder, each into one share of the common stock of the Company. In addition the Company issued one Special Preferred Voting Share (the “Special Preferred Share”) (Note 9).

 

As a result of the shareholders of Bionik Canada having a controlling interest in the Company subsequent to the Merger, for accounting purposes the Merger does not constitute a business combination. The transaction has been accounted for as a recapitalization of the Company with Bionik Canada being the accounting acquirer even though the legal acquirer is Bionik, accordingly, the historic financial statements of Bionik Canada are presented as the comparative balances for the period prior to the Merger.

 

References to the Company refer to the Company and its wholly owned subsidiaries, Bionik Acquisition Inc., Bionik, Inc. (the former IMT) and Bionik Canada. References to Drywave relate to the Company prior to the Merger.

 

On April 21, 2016, the Company acquired all of the outstanding shares and, accordingly, all assets and liabilities of Interactive Motion Technologies, Inc. (IMT), a Boston, Massachusetts-based global pioneer and leader in providing effective robotic products for neurorehabilitation, pursuant to an Agreement and Plan of Merger (the “Merger Agreement”) dated March 1, 2016, with IMT, Hermano Igo Krebs, and Bionik Mergerco Inc., a Massachusetts corporation and our wholly owned subsidiary (Bionik Mergerco). The merger agreement provided for the merger of Bionik Mergerco with and into IMT, with IMT surviving the merger as the Company’s wholly owned subsidiary. In return for acquiring IMT, IMT shareholders received an aggregate of 23,650,000 shares of the Company’s common stock.

 

The Company is a global pioneering robotics company focused on providing rehabilitation solutions to individuals with neurological disorders, specializing in designing, developing and commercializing cost-effective physical rehabilitation technologies, prosthetics, and assisted robotic products. The Company strives to innovate and build devices that can rehabilitate and improve an individual’s health, comfort, accessibility and quality of life through the use of advanced algorithms and sensing technologies that anticipate a user’s every move.

 

The unaudited condensed consolidated interim financial statements consolidate the Company and its wholly owned subsidiaries Bionik Canada, Bionik Acquisition Inc. and Bionik, Inc. (the former IMT) since its acquisition on April 21, 2016. These unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), which contemplates continuation of the Company as a going concern.

 

The Company’s principal offices are located at 483 Bay Street, N105, Toronto, Ontario, Canada M5G 2C9 and Bionik, Inc.’s address is 80 Coolidge Hill Road, Watertown, MA. USA 02472.

 

 8 

 

 

BIONIK LABORATORIES CORP.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three and nine month periods ended December 31, 2016 and 2015

(unaudited) (Amounts expressed in U.S. Dollars)

 

1.NATURE OF OPERATIONS AND GOING CONCERN (continued)

 

Going Concern

 

As at December 31, 2016, the Company had a working capital deficit of $3,434,290 (working capital as at March 31, 2016, of $187,156) and an accumulated deficit of $14,056,624 (March 31, 2016 - $11,651,980) and the Company incurred a net loss and comprehensive loss of $2,404,644 for the nine-month period ended December 31, 2016 (December 31, 2015 – net income of $2,040,240).

 

There is no certainty that the Company will be successful in generating sufficient cash flow from operations or achieving and maintaining profitable operations in the future to enable it to meet its obligations as they come due and consequently continue as a going concern. The Company will require additional financing this year to fund its operations and it is currently working on securing this funding through corporate collaborations, public or private equity offerings or debt financings. Sales of additional equity securities by the Company would result in the dilution of the interests of existing stockholders. There can be no assurance that financing will be available when required. In the event that the necessary additional financing is not obtained, the Company would reduce its discretionary overhead costs substantially or otherwise curtail operations.

 

The Company expects the forgoing, or a combination thereof, to meet the Company's anticipated cash requirements for the next 12 months; however, these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on recoverability and reclassification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

 

The unaudited condensed interim financial statements do not include any adjustments related to the recoverability and classification of the recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. All adjustments, consisting only of normal recurring items, considered necessary for fair presentation have been included in these financial statements.

 

2.SIGNIFICANT ACCOUNTING POLICIES

 

Unaudited Condensed Consolidated Interim Financial Statements

 

These unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual audited financial statements and should be read in conjunction with those annual audited financial statements filed on Form 10-KT for the year ended March 31, 2016. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period.

 

Newly Adopted and Recently Issued Accounting Pronouncements

 

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2017. Early adoption is not permitted. The impact on the consolidated financial statements of adopting ASU 2014-09 will be assessed by management.

 

In August 2014, the FASB issued a new financial accounting standard on going concern, ASU No. 2014-15, “Presentation of Financial Statements – Going Concern (Sub-Topic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The standard provides guidance about management’s responsibility to evaluate whether there is a substantial doubt about the organization’s ability to continue as a going concern. The amendments in this Update apply to all companies. They become effective in the annual period ending after December 15, 2016, with early application permitted. The impact on the consolidated financial statements of adopting ASU 2014-15 will be assessed by management.

 

In September 2015, the FASB issued ASU No. 2015-16, “Simplifying the Accounting for Measurement-Period Adjustments,” which illustrates certain guidance governing adjustments to the provisional amounts recognized at the acquisition date with a corresponding adjustment to goodwill. Such adjustments are required when new information is obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement amounts initially recognized or would have resulted in the recognition of additional assets and liabilities. ASU No. 2015-16 eliminates the requirement to retrospectively account for such adjustments. ASU No. 2015-16 is effective for the fiscal year commencing after December 15, 2016. The Company has adopted this ASU No. 2015-16 as at and for the three and twelve-month periods ended March 31, 2016. There was no material effect on the consolidated financial position or the consolidated results of operations and comprehensive income (loss).

 

 9 

 

 

 

BIONIK LABORATORIES CORP.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three and nine month periods ended December 31, 2016 and 2015

(unaudited) (Amounts expressed in U.S. Dollars)

 

2.SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes,” which requires that deferred tax liabilities and assets be classified on our Consolidated Balance Sheets as noncurrent based on an analysis of each taxpaying component within a jurisdiction. ASU No. 2015-17 is effective for the fiscal year commencing after December 15, 2017. The Company does not anticipate that the adoption of ASU No. 2015-17 will have a material effect on the consolidated financial position or the consolidated results of operations.

 

In February 2016, the FASB issued ASU 2016-02, Leases. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company is still assessing the impact that the adoption of ASI 2016-02 will have on the consolidated financial position and the consolidated results of operations.

 

In March 2016, the FASB issued ASU 2016-09, “Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting”. Several aspects of the accounting for share-based payment award transaction are simplified, including (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company is still assessing the impact that the adoption of ASI 2016-09 will have on the consolidated financial position and the consolidated results of operations.

 

In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. This ASU provides eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for the fiscal year commencing after November 1, 2018. The Company is still assessing the impact that the adoption of ASI 2016-15 will have on the consolidated statement of cash flows.

 

In January 2017, the FASB issued ASU 2017-01, “Business Combinations: Clarifying the definition of a Business” which amends the current definition of a business. Under ASU 2017-01, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contributes to the ability to create outputs. ASU 2017-01 further states that when substantially all of the fair value of gross assets acquitted is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. The new guidance also narrows the definition of the term “outputs” to be consistent with how it is described in Topic 606, Revenue from Contracts with Customers. The changes to the definition of a business will likely result in more acquisitions being accounted for as asset acquisitions. ASU 2017-01 is effective for acquisitions commencing on or after June 30, 2019, with early adoption permitted. Adoption of this guidance will be applied prospectively on or after the effective date.

 

In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other” ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test, which required a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. ASU 2017-04 is effective for financial statements issued for fiscal years, and interim periods beginning after December 15, 2019.

 

Inventories

 

Inventory is stated at the lower of cost or market. Cost is recorded at standard cost, which approximates actual cost, on the first-in first-out basis. Work in progress and finished goods consist of materials, labor and allocated overhead.

 

Revenue Recognition

 

The Company recognizes revenue from product sales when persuasive evidence of an agreement with customer exists, products are shipped or title passes pursuant to the terms of the agreement, the amount due from the customer is fixed or determinable, collectability is reasonably assured, and there is no significant future performance obligation. Deposits are carried as liabilities until the requirements for revenue recognition are met.

 

Significant Judgments - Warrant Derivative Liability

 

The Company’s derivative warrant instruments are measured at fair value using a simulation model which takes into account, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock, its expected volatility, holding cost and the risk- free interest rate for the term of the warrant (Note 11). The warrant derivative liability is revalued at each reporting period and changes in fair value are recognized in the condensed consolidated interim statements of operations and comprehensive loss under the caption “Change in fair value of warrant derivative liability”.

 

 10 

 

 

BIONIK LABORATORIES CORP.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three and nine month periods ended December 31, 2016 and 2015

(unaudited) (Amounts expressed in U.S. Dollars)

 

2.SIGNIFICANT ACCOUNTING POLICIES (continued)

 

The selection of the appropriate valuation model and the inputs and assumptions that are required to determine the valuation requires significant judgment and requires management to make estimates and assumptions that affect the reported amount of the related liability and reported amounts of the change in fair value. Actual results could differ from those estimates, and changes in these estimates are recorded when known. As the derivative warrant liability is required to be measured at fair value at each reporting date it is reasonably possible that these estimates and assumptions could change in the near term.

 

Warranty Reserve and Deferred Warranty Revenue

 

The Company provides a one-year warranty as part of its normal sales offering. When products are sold, the Company provides warranty reserves, which, based on the historical experience of the Company are sufficient to cover warranty claims. Accrued warranty reserves are included in accrued liabilities on the balance sheet and amounted to $64,957 at December 31, 2016 (March 31, 2016 - $Nil). The Company also sells extended warranties for additional periods beyond the standard warranty. Extended warranty revenue is deferred and recognized as revenue over the extended warranty period. The Company recognized $15,355 and $30,732 of expenses related to the change in warranty reserves and warranty costs incurred and recorded as an expense in cost of goods sold during the three and nine-month period ended December 31, 2016 (March 31, 2016 - $Nil).

 

Foreign Currency Translation

 

On April 1, 2015, Bionik Canada and Bionik Acquisition Inc. changed its functional currency from the Canadian Dollar to the U.S. Dollar. This reflects the fact that the majority of the Company’s business is influenced by an economic environment denominated in U.S. currency as well the Company anticipates revenues to be earned in U.S. dollars. The change in accounting treatment was applied prospectively. The functional currency is separately determined for the Company and each of its subsidiaries, and is used to measure the financial position and operating results. The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.

 

Fair Value of Financial Instruments

 

ASC Topic 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Included in the ASC Topic 820 framework is a three level valuation inputs hierarchy with Level 1 being inputs and transactions that can be effectively fully observed by market participants spanning to Level 3 where estimates are unobservable by market participants outside of the Company and must be estimated using assumptions developed by the Company. The Company discloses the lowest level input significant to each category of asset or liability valued within the scope of ASC Topic 820 and the valuation method as exchange, income or use. The Company uses inputs, which are as observable as possible, and the methods most applicable to the specific situation of each company or valued item.

 

The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, other receivables, accounts payable and accrued liabilities, due from related parties approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest. Per ASC Topic 820 framework these are considered Level 2 inputs where inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

As at December 31, 2016, the Company’s warrant derivative liability was measured at fair value at each reporting period using a simulation model based on Level 3 inputs.

 

The Company’s policy is to recognize transfers into and out of Level 3 as of the date of the event or change in the circumstances that caused the transfer. There were no such transfers during the period.

 

 11 

 

 

BIONIK LABORATORIES CORP.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three and nine month periods ended December 31, 2016 and 2015

(unaudited) (Amounts expressed in U.S. Dollars)

 

3.ACQUISITION

 

On April 21, 2016, the Company acquired 100% of the common and preferred shares of IMT, through a transaction where Bionik Mergerco merged with and into IMT, with IMT surviving the Merger as a wholly owned subsidiary of Bionik.

 

Subject to the indemnification and escrow arrangements described in the Merger Agreement, Bionik issued an aggregate of 23,650,000 shares of Company Common Stock in exchange for all shares of IMT Common Stock and IMT Preferred Stock outstanding immediately prior to April 21, 2016. All shares have been issued at December 31, 2016.

 

Bionik also assumed each of the 3,895,000 options to acquire IMT Common Stock granted under IMT’s equity incentive plan or otherwise issued by IMT. These options were exchanged for purchase of an aggregate of 3,000,000 shares of Company Common Stock, of which 1,000,000 have an exercise price of $0.25. 1,000,000 have an exercise price of $0.95 and 1,000,000 have an exercise price of $1.05. Stock compensation expense on vested options of $2,582,890 was recorded on the options exchanged and this amount is included in the acquisition equation.

 

As a result of the acquisition of IMT, the Company acquired assets including three licensed patents, an MIT License Agreement, three FDA listed products, an FDA inspected manufacturing facility, extensive clinical and sales data, and international distributors. Due to the complexities in identifying and valuing the intangible assets acquired, the Company has not yet finalized the purchase price allocation. At this time the Company is not practicably able to estimate the fair value of each identifiable asset. The Company has retained an independent valuator to determine the purchase price allocation. At this time the Company anticipates the intangible assets to consist of clinical data, sales data, license and patents/technology acquired and any excess to result in goodwill.

 

The following sets forth the preliminary purchase price allocation based on management’s best estimates of fair value, including a summary of major classes of consideration transferred and the recognized amounts of assets acquired and liabilities assumed at the acquisition date.

 

   As at 
   April 21, 2016 
   $ 
Fair value of 23,650,000 common shares (a)   23,177,000 
Fair value of vested stock options (b)   2,582,890 
    25,759,890 
      
Allocation of purchase price:     
Cash and cash equivalents   266,635 
Accounts receivable   6,490 
Inventories   188,879 
Prepaid expenses and other current assets   16,839 
Equipment   59,749 
      
Liabilities assumed:     
Accounts payable   (241,299)
Accrued liabilities   (361,029)
Customer deposits   (86,487)
Demand notes payable   (324,894)
Promissory notes payable   (217,808)
Bionik advance   (1,436,164)
Net assets acquired   (2,129,089)
Intangible assets and goodwill   27,888,979 
    25,759,890 

 

(a)The fair value of common shares is based on $0.98 the closing market price of the Company’s common stock on April 21, 2016.

 

(b)The fair value of the vested stock options was determined using the Black-Scholes option pricing model with the following key assumptions: a risk free rate of 1.59%, dividend and forfeiture rates of 0% and expected volatility of 114% which is consistent with the Company’s assumptions (Note 10).

 

 12 

 

 

BIONIK LABORATORIES CORP.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three and nine month periods ended December 31, 2016 and 2015

(unaudited) (Amounts expressed in U.S. Dollars)

 

3.ACQUISITION (continued)

 

The amount of IMT’s revenue and net loss and comprehensive loss included in the Company’s condensed consolidated interim statements of operations and comprehensive loss for the three and nine-month period ended December 31, 2016 are as follows:

 

   For the period
Oct. 1 - Dec. 31, 2016
  

For the period

April 21 - Dec. 31, 2016

 
Revenue  $372,426   $553,900 
           
Net loss and comprehensive loss  $(662,563)  $(1,506,249)

 

Pro forma results of operations

 

The following unaudited pro forma financial information presents combined results of operations for each of the periods presented as if the Merger had been completed April 1, 2016. The pro forma data is for informational purposes only and is not necessarily indicative of the consolidated results of operations of the combined business had the Merger actually occurred on April 1, 2016 or the results of future operations of the combined business. For instance, planned or expected operational synergies following the Merger are not reflected in the pro forma information. Consequently, actual result will differ from the unaudited pro forma information presented below.

 

   Three Months Ended
December 31,
  

Nine Months Ended

December 31,

 
   2016   2015   2016   2015 
Revenue  $372,426   $987,494   $557,340   $1,800,437 
                     
Net (loss) income and comprehensive (loss) income  $(810,418)  $833,706   $(2,592,024)  $1,314,766 

 

*There were no material or nonrecurring adjustments in the supplemental pro forma revenue or results of operations as shown above.

 

4.PREPAID EXPENSES AND OTHER RECEIVABLES

 

   Dec. 31,   March 31, 
   2016   2016 
   $   $ 
Prepaid expenses and sundry receivables   92,236    87,979 
Prepaid insurance   32,716    107,259 
Sales taxes receivable (i)   28,058    36,495 
    153,010    231,733 

 

(i)Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

 

 13 

 

 

BIONIK LABORATORIES CORP.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three and nine month periods ended December 31, 2016 and 2015

(unaudited) (Amounts expressed in U.S. Dollars)

 

5.INVENTORIES

 

   Dec. 31,   March 31, 
   2016   2016 
  $   $ 
Raw Materials   169,173    - 
Work in Progress   25,400    - 
    194,573    - 

 

During the period ended December 31, 2016, $43,009 of inventory has been written off as it is not expected to be used as a result of the introduction of new versions of existing InMotion products as well as $129,416, which was provided for due to an interim sample count on inventory at December 31, 2016.

 

6.EQUIPMENT

 

Equipment consisted of the following as at December 31, 2016 and March 31, 2016:

 

   December 31, 2016   March 31, 2016 
       Accumulated           Accumulated     
   Cost   Depreciation   Net   Cost   Depreciation   Net 
Computers and electronics   165,003    117,632    47,371    152,246    96,379    55,867 
Capital leases of IT equipment   23,019    2,303    20,716    -    -    - 
Furniture and fixtures   27,496    12,289    15,207    22,496    10,118    12,378 
Demonstration equipment   144,000    30,859    113,141    -    -    - 
Tools and parts   11,422    4,112    7,310    11,422    2,917    8,505 
    370,940    167,195    203,745    186,164    109,414    76,750 

 

Included in computers and electronics are assets under capital lease of $23,019 which are being amortized over the term of the lease. Current portion of the lease as at December 31, 2016, $4,603 (March 31, 2016 - $Nil) and the long-term portion as at December 31 2016, $15,729 (March 31, 2016 - $Nil). Equipment is recorded at cost less accumulated depreciation. Depreciation expense during the three and nine-month periods ended December 31, 2016 was $24,028 and $57,781 (December 31, 2015 - $20,877 and $53,357).

 

7.NOTES PAYABLE

 

Demand Notes payable

 

The Company has outstanding notes payable (“Notes”) of $324,894, acquired from IMT on April 20, 2016. Loan amounts represented by one such Note are owed to a director of the Company for $149,688 at December 31, 2016. On March 1, 2016, the Company executed amendments to the Notes to accrue interest at a rate of prime, as reported by the Wall Street Journal, of 3.50% at the date of amendment and to defer the demand feature until the earlier of December 31, 2017 or the date when the Company raises new capital in excess of $15 million in cash.

 

Balance, March 31, 2016  $- 
Acquisition of IMT (Note 3)   324,894 
Accrued interest   3,467 
Balance, December 31, 2016  $328,361 

 

Interest expense incurred on the Notes totaled $2,367 and $3,467 for the three and nine-month period ended December 31, 2016, which are included in accrued liabilities.

 

Promissory Notes payable

 

In February 2014, the Company borrowed $200,000 from an existing investor under the terms of the secured promissory note (“Promissory Note”). The Promissory Note bears interest at a simple interest rate equal to 10% per annum and interest is payable quarterly. The Promissory Note, which matured in March 2016 and then September 2016, was further extended and now matures March 2017, may be prepaid at any time, and is secured by substantially all the assets of one of the Company’s subsidiaries. Interest expense incurred on the Promissory Note totaled $5,041 and $13,973 for the three and nine month periods ended December 31, 2016.

 

Balance, March 31, 2016  $- 
Acquisition of IMT (Note 3)   217,808 
Accrued interest   13,973 
Balance, December 31, 2016  $231,781 

 

 14 

 

 

BIONIK LABORATORIES CORP.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three and nine month periods ended December 31, 2016 and 2015

(unaudited) (Amounts expressed in U.S. Dollars)

 

7.NOTES PAYABLE (continued)

 

Convertible Notes Payable

 

In December 2016, several non-related shareholders of the Company agreed to loan the Company $1,500,000, in three tranches, $500,000 upon origination of the loans and $500,000 on each of January 15 and February 15, 2017. At December 31, 2016, $483,333 of the initial $500,000 loans was received. The loans bear interest at 6% and are due for repayment on March 31, 2017. Under certain conditions these loans can be converted into Company shares. If the loans are not repaid or the shareholders decide not to convert their loans into common shares of the Company, these shareholders will take security over all assets of the Company.

 

8.RELATED PARTY TRANSACTIONS AND BALANCES

 

Due from related parties

 

(a)As of December 31, 2016, the Company had advances receivable from the Chief Operating Officer (“COO”) and former Chief Technology Officer (“CTO”) for $40,913 (March 31, 2016 - $41,445). These advances are unsecured, bear interest at a rate of 1% based on the Canada Revenue Agency’s prescribed rate for such advances and are payable on demand in Canadian dollars. The Company, at December 31, 2016, has accrued interest receivable in the amount of $1,177 (March 31, 2016 - $1,148); the remaining fluctuation in the balance from the prior year is due to foreign exchange.

 

Accounts payable and accrued liabilities

 

(b)As at December 31, 2016, $28,081 (March 31, 2016 - $2,694) was owing to the CEO, $Nil (March 31, 2016 - $3,284) was owing to the former CTO, $11,815, was owing to the COO (March 31, 2016 - $8,812), $2,671 was owing to the CFO (March 31, 2016 - $116), and $5,054 was owing to our Chief Commercial Officer (March 31, 2016 - $Nil), in each case related to business expenses, all of which are included in accounts payable and accrued liabilities.

 

9.SHARE CAPITAL

 

   December 31, 2016   March 31, 2016 
   Number of       Number of     
   shares   $   Shares   $ 
Exchangeable Shares:                    
Balance beginning and end of period   50,000,000    50,000    50,000,000    50,000 
Common Shares                    
Balance at beginning of the period   22,591,292    22,591    22,428,313    22,428 
Shares issued on acquisition (Note 3)   23,650,000    23,650    -    - 
Shares issued for services (v)   70,000    70    117,471    117 
Cashless exercise of warrants (iv)   51,249    51    45,508    46 
Balance at end of the period   46,362,541    46,362    22,591,292    22,591 
TOTAL COMMON SHARES   96,362,541    96,362    72,591,292    72,591 

 

(i)On April 21, 2015, the Company issued 3,115,000 Units for gross proceeds of $2,492,000 to accredited investors in a fourth closing (the “Fourth Closing”) of its 2015 private offering. Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs before legal and other related to the Fourth Closing of $338,960 and issued 311,500 broker warrants exercisable at $0.80 for a period of 4 years. The warrants were measured at fair value and recorded as a warrant liability on the consolidated balance sheet (Note 11). The fair value of the warrants exceeded the net proceeds received upon closing and as a result $435,682 was recorded as a loss on initial recognition of the warrants and included in the change in fair value of warrant derivative liability on the consolidated statements of operations and comprehensive loss.

 

(ii)On May 27, 2015, the Company issued 1,418,750 Units for gross proceeds of $1,135,000 to accredited investors in a fifth closing (the “Fifth Closing”) of its 2015 private offering. Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs before legal and other costs related to the Fifth Closing of $147,566 and issued 141,875 broker warrants exercisable at $0.80 for a period of 4 years. The warrants were measured at fair value and recorded as a warrant liability on the consolidated balance sheet (Note 11). The fair value of the warrants exceeded the net proceeds received upon closing and as a result $37,739 was recorded as a loss on initial recognition of the warrants and included in the change in fair value of warrant derivative liability on the consolidated statements of operations and comprehensive loss.

 

 15 

 

 

BIONIK LABORATORIES CORP.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three and nine month periods ended December 31, 2016 and 2015

(unaudited) (Amounts expressed in U.S. Dollars)

 

9.SHARE CAPITAL (Continued)

 

(iii)On June 30, 2015, the Company issued 2,035,000 Units for gross proceeds of $1,628,000 to accredited investors in a sixth and final closing (the “Sixth Closing”) of its private offering. Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs before legal and other costs related to the Sixth Closing of $211,656 and issued 203,500 broker warrants exercisable at $0.80 for a period of 4 years. The warrants were measured at fair value and recorded as a warrant liability on the consolidated balance sheet (Note 11). The fair value of the warrants exceeded the net proceeds received upon closing and as a result $74,625 was recorded as a loss on initial recognition of the warrants and included in the change in fair value of warrant derivative liability on the consolidated statements of operations and comprehensive loss.

 

(iv)During the nine-month period ended December 31, 2016, 51,249 common shares were issued as a result of a cashless exercise of 262,045 warrants with an exercise price of $0.80. Under the terms of the warrant agreement the value of the warrants on exercise is attributed to the shares on exercise and the Company has recognized a value of $43,562.

 

(v)The Company issued 70,000 common shares during the nine-month period ended December 31, 2016 for consulting services and recognized $59,500 of share-based compensation expense.

 

Special Voting Preferred Share

 

In connection with the Merger (Note 1), on February 26, 2015, the Company entered into a voting and exchange trust agreement (the “Trust Agreement”). Pursuant to the Trust Agreement, the Company issued one Special Voting Preferred Share to the Trustee, and the parties created a trust for the Trustee to hold the Special Voting Preferred Share for the benefit of the holders of the Exchangeable Shares (the “Beneficiaries”). Pursuant to the Trust Agreement, the Beneficiaries will have voting rights in the Company equivalent to what they would have had they received shares of common stock in the same amount as the Exchangeable Shares held by the Beneficiaries.

 

In connection with the Merger and the Trust Agreement, effective February 20, 2015, the Company filed a certificate of designation of the Special Voting Preferred Share (the “Special Voting Certificate of Designation”) with the Delaware Secretary of State. Pursuant to the Special Voting Certificate of Designation, one share of the Company’s blank check preferred stock was designated as Special Voting Preferred Share. The Special Voting Preferred Share entitles the Trustee to exercise the number of votes equal to the number of Exchangeable Shares outstanding on a one-for-one basis during the term of the Trust Agreement.

 

The Special Voting Preferred Share is not entitled to receive any dividends or to receive any assets of the Company upon liquidation, and is not convertible into common shares of the Company.

 

The voting rights of the Special Voting Preferred Share will terminate pursuant to and in accordance with the Trust Agreement. The Special Voting Preferred Share will be automatically cancelled at such time as no Exchangeable Shares are held by a Beneficiary.

 

 16 

 

 

BIONIK LABORATORIES CORP.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three and nine month periods ended December 31, 2016 and 2015

(unaudited) (Amounts expressed in U.S. Dollars)

 

10.STOCK OPTIONS

 

The purpose of the Company’s stock option plan, is to attract, retain and motivate persons of training, experience and leadership to the Company, including their directors, officers and employees, and to advance the interests of the Company by providing such persons with the opportunity, through share options, to acquire an increased proprietary interest in the Company.

 

Options may be granted in respect of authorized and unissued shares, provided that the aggregate number of shares reserved for issuance upon the exercise of all Options granted under the Plan shall not exceed 15% of the shares of common stock and Exchangeable Shares issued and outstanding (determined as of January 1 of each year). Optioned shares in respect of which options are not exercised shall be available for subsequent options.

 

On April 11, 2014 and June 20, 2014 the Company issued 657,430 and 264,230 options to employees and a consultant at an exercise price of $0.165 and $0.23, respectively, with a term of seven years. The options vest one-third on grant date and two thirds equally over the subsequent two years on the anniversary date. During the nine-month period ended December 31, 2014, 125,824 of the 657,430 options were cancelled. On February 26, 2015, as a result of the Merger, the options were re-valued. The fair value, as re-measured, of the 531,606 options issued in April 2014 and the 264,230 options issued in June 2014 was $230,930 and $118,957 respectively. An additional 62,912 options were cancelled during the quarter ended June 30, 2016. Stock compensation has been fully expensed on these options and so there is no compensation expense in the three months ended December 31, 2016 however there was $3,834 was recognized in the nine months ended December 31, 2016.

 

On July 1, 2014, the Company issued 2,972,592 options to management of the Company, at an exercise price of $0.23 with a term of 7 years, which vested May 27, 2015. On February 26, 2015, as a result of the Merger, the options were re-valued at a fair value of $1,259,487, which vested immediately. On October 8, 2016, 990,864 of these options expired.

 

On February 17, 2015, the Company issued 314,560 options to a director, employees and a consultant with an exercise price of $0.23, that vest one third immediately and two thirds over the next two anniversary dates with an expiry date of seven years. The grant date fair value of the options was $136,613. During the nine months ended December 31, 2016, 110,100 options were cancelled and $7,400 of stock compensation was recognized in the quarter and $22,200 of stock compensation was recognized for the nine months ended December 31, 2016.

 

On November 24, 2015, the Company issued 650,000 options granted to employees that vest over three years at the anniversary date. The grant date fair value of the options was $694,384. During the year ended March 31, 2016 250,000 options were cancelled and stock compensation expense of $62,317 was recognized. During the quarter ended December 31, 2016, $35,609 of stock compensation expense was recognized and for the nine months ended December 31, 2016, $106,828 of stock compensation was recognized.

 

On December 14, 2015, the Company issued 2,495,000 options granted to employees, directors and consultants that vest over three years at the anniversary date. The grant date fair value of the options was $1,260,437. During the year ended March 31, 2016, 25,000 options were cancelled and for the quarter ended June 30, 2016 40,000 options were cancelled and for the three months ended December 31, 2016 stock compensation expenses of $102,300 was recognized. For the nine months ended December 31, 2016, stock compensation expense of $304,908 was recognized.

 

On April 21, 2016, the Company issued 3,000,000 stock options to employees of Bionik, Inc. in exchange for 3,895,000 options that existed before the Company purchased IMT, of which 1,000,000 have an exercise price of $0.25, 1,000,000 has an exercise price of $0.95 and 1,000,000 have an exercise price of $1.05. The grant fair value of vested options was $2,582,890 and has been recorded as part of the acquisition equation (Note 3). For options that have not yet vested $10,169 of compensation expense was recognized in the quarter ended December 31, 2016 and $20,177 for the nine months ended December 31, 2016.

 

On April 26, 2016, the Company issued 250,000 options to an employee with an exercise price of $1.00 that will vest over three years at the anniversary date. The grant fair value was $213,750. During the quarter ended December 31, 2016, $17,813 of stock compensation expense was recognized. For the nine months ended December 31 2016, $48,292 of stock compensation expense was recognized.

 

On August 8, 2016, the Company issued 750,000 options to an employee with an exercise price of $1.00 that will vest over three years at the anniversary date. The grant fair value was $652,068. During the quarter ended December 31, 2016, $54,339 of stock compensation expense was recognized and for the nine months ended December 31, 2016 $85,891 of stock compensation was recognized.

 

During the three-month period ended December 31, 2016, the Company recorded $227,630 in share-based compensation related to the vesting of stock options (December 31, 2015 - $13,311). During the nine-month period ended December 31, 2016, the Company recorded $592,130 in share-based compensation related to the vesting of stock options (December 31, 2015 - $1,337,593).

 

 17 

 

 

BIONIK LABORATORIES CORP.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three and nine month periods ended December 31, 2016 and 2015

(unaudited) (Amounts expressed in U.S. Dollars)

 

10.STOCK OPTIONS (continued)

 

These options at their respective grant dates were valued using the Black-Scholes option pricing model with the following key assumptions:

 

   Expected life   Risk   Dividend   Forfeiture   Expected   Grant date 
Grant date  in years   free rate   rate   rate   volatility   fair value 
February 17, 2015   5.39    1.59%   0%   0%   114%  $136,613 
July 1, 2014   4.75    1.59%   0%   0%   114%  $1,259,487 
June 20, 2014   4.72    1.59%   0%   0%   114%  $118,957 
April 11, 2014   4.50    1.59%   0%   0%   114%  $230,930 
November 24, 2015   6.15    1.59%   0%   0%   114%  $694,384 
December 14, 2015   6.21    1.59%   0%   0%   114%  $1,260,437 
April 21, 2016   0.79-9.25    1.59%   0%   0%   114%  $2,582,890 
April 26, 2016   6.57    1.59%   0%   0%   114%  $213,750 
August 8, 2016   6.86    1.59%   0%   0%   114%  $652,068 

 

       Weighted-Average 
   Number of Options   Exercise Price ($) 
Outstanding, March 31, 2016    6,604,880    0.57 
Issued    4,000,000    0.81 
Cancelled    (1,134,001)   0.26 
Outstanding, December 31, 2016    9,470,879    0.71 

 

 18 

 

 

BIONIK LABORATORIES CORP.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three and nine month periods ended December 31, 2016 and 2015

(unaudited) (Amounts expressed in U.S. Dollars)

 

10.STOCK OPTIONS (continued)

 

The following is a summary of stock options outstanding and exercisable as of December 31, 2016:

 

           Number of 
Exercise Price ($)   Number of Options   Expiry Date  Exercisable Options 
 0.165    374,324   April 1, 2021   374,324 
 0.23    99,610   June 20, 2021   99,610 
 0.23    1,981,728   July 1, 2021   1,981,728 
 0.23    204,460   February 17, 2022   136,314 
 1.22    400,000   November 24, 2022   133,333 
 1.00    2,430,000   December 14, 2022   810,000 
 1.00    250,000   April 26, 2023   - 
 0.25    906,077   July 28, 2025   906,077 
 0.25    86,972   December 30, 2025   59,158 
 0.95    9,486   February 2, 2017   9,486 
 0.95    111,937   March 28, 2023   111,937 
 0.95    31,620   March 3, 2024   31,620 
 0.95    15,810   March 14, 2024   15,810 
 0.95    82,213   September 30, 2024   82,213 
 0.95    7,431   June 2, 2025   7,431 
 0.95    671,859   July 29, 2025   671,859 
 0.95    57,353   December 30, 2025   8,193 
 1.05    36,697   February 2, 2017   36,697 
 1.05    433,027   March 28, 2023   433,027 
 1.05    122,324   March 3, 2024   122,324 
 1.05    61,162   March 14, 2024   61,162 
 1.05    318,042   September 30, 2024   318,042 
 1.05    28,747   June 2, 2025   28,747 
 1.00    750,000   August 8, 2023   - 
      9,470,879       6,439,092 

 

The weighted-average remaining contractual term of the outstanding options is 6.20 (December 31, 2015 – 6.16) and for the options that are exercisable the weighted average is 6.19 (December 31, 2015 – 5.49).

 

11.WARRANTS

 

The following is a continuity schedule of the Company’s common share purchase warrants:

 

   Number of   Average 
   Warrants   Exercise Price ($) 
Outstanding and exercisable, March 31, 2015   10,823,450    1.35 
Issued   7,225,625    1.35 
Outstanding and exercisable, December 31, 2015   18,049,075    1.35 
Exercised   (148,787)   (0.80)
Outstanding and exercisable, March 31, 2016   17,900,288    1.35 
Exercised   (262,045)   (0.80)
Outstanding and exercisable, December 31, 2016   17,638,243    1.36 

 

In February 2016, a warrant holder exercised 148,787 warrants on a cashless basis based on the terms of the warrant agreement and was issued 45,508 common shares. During the nine-month period ended December 31, 2016, 262,045 warrants were exercised on a cashless basis based on the terms of the warrant agreement and the Company issued 51,249 common shares (Note 9 (iv)).

 

 19 

 

 

BIONIK LABORATORIES CORP.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three and nine month periods ended December 31, 2016 and 2015

(unaudited) (Amounts expressed in U.S. Dollars)

 

11.WARRANTS (continued)

 

Common share purchase warrants

 

The following is a summary of common share purchase warrants outstanding as of December 31, 2016:

 

Exercise
Price ($)
    

Number of

Warrants

  
1.40       7,735,750   February 26, 2019
 1.40       1,212,500   March 27, 2019
 1.40       891,250   March 31, 2019
 1.40   Note 9(i)   3,115,000   April 21, 2019
 1.40   Note 9 (ii)   1,418,750   May 27, 2019
 1.40   Note 9(iii)   2,035,000   June 30, 2019
 0.80   Note 9 (i) to (iii)   1,229,993   February 26, 2019
         17,638,243    

 

The weighted-average remaining contractual term of the outstanding warrants is 2.25 (March 31, 2016 - 2.77).

 

Exchangeable share purchase warrants

 

In 2014, the Company repaid loans of $180,940 plus accrued interest of $12,138 owing to investors introduced by Pope and Co. As part of this transaction the Company was committed to issue these lenders warrants exercisable into 349,522 Exchangeable Shares at an exercise price of $0.23 per share for a period ending March 21, 2017. During the year ended March 31, 2015, the Company issued these warrants.

 

Warrant derivative liability

 

The Company’s outstanding common share purchase warrants include price protection provisions that allow for a reduction in the exercise price of the warrants in the event the Company subsequently issues common stock or options, rights, warrants or securities convertible or exchangeable for shares of common stock at a price lower than the exercise price of the warrants. Simultaneously with any reduction to the exercise price, the number of shares of common stock that may be purchased upon exercise of each of these warrants shall be increased based on a pre-defined formula.

 

In addition, prior to the effectiveness of certain resale registration statements or if any such registration statements are no longer effective, the holder of the Company’s warrants, at their option, may exercise all or any part of the warrants in a “cashless” or “net-issue” exercise.

 

The Company has the option to redeem the warrants for $0.001 per warrant if the daily volume weighted-average price of the common shares is 200% or more of the exercise price for twenty consecutive trading days provided there is an effective registration statement covering the common shares available throughout the thirty-day period after the redemption date. The warrant holders then have thirty days to exercise the warrants or receive the redemption amount.

 

The Company’s derivative instruments have been measured at fair value at inception and at each reporting period using a simulation model. The Company recognizes all of its warrants with price protection on its consolidated balance sheet as a derivative liability.

 

 20 

 

 

BIONIK LABORATORIES CORP.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three and nine month periods ended December 31, 2016 and 2015

(unaudited) (Amounts expressed in U.S. Dollars)

 

11.WARRANTS (continued)

 

The following summarizes the changes in the value of the warrant derivative liability from inception until December 31, 2016:

 

   Number of
Warrants
   Value ($) 
Balance at March 31, 2015   10,823,450    8,382,648 
Warrants issued in April 21, 2015 financing   3,426,500    2,588,722 
Warrants issued in May 27, 2015 financing   1,560,625    1,025,173 
Warrants issued in June 30, 2015 financing   2,238,500    1,490,969 
Change in fair value of warrant derivative liability   -    (7,419,643)
Balance at December 31, 2015   18,049,075    6,067,869 
Fair value of warrants exercised   (148,787)   (60,966)
Change in fair value of warrant derivative liability   -    (870,913)
Balance at March 31, 2016   17,900,288    5,135,990 
Change in fair value of warrant derivative liability   -    (2,510,388)
Fair value of warrants exercised   (262,045)   (43,562)
Balance at December 31, 2016   17,638,243    2,582,040 

 

During the nine-month period ended December 31, 2016, the Company recorded a gain of $2,510,388 (December 31, 2015 - $7,419,643) on re-measurement of the warrant liability to fair value. The change is recorded as a change in fair value of warrant derivative liability within the Company’s consolidated statement of operations and comprehensive (loss) income.

 

The key inputs and assumptions used in the simulation model at inception and at December 31, 3016 and March 31, 2016 are as follows:

 

       Expected                     
   Number of   life in   Exercise Price   Risk free   Dividend   Expected   Fair 
Grant date  Warrants   years   ($)   rate   Rate   Volatility   value ($) 
At Inception:                                   
February 26, 2015   7,735,750    4    1.4    0.44%   0%   51.83%   464,784 
February 26, 2015   773,575    4    0.8    0.44%   0%   51.83%   85,590 
March 27, 2015   1,212,500    3.92    1.4    0.43%   0%   52.37%   950,913 
March 27, 2015   121,250    3.92    0.8    0.43%   0%   52.37%   85,412 
March 31, 2015   891,250    3.91    1.4    0.41%   0%   52.45%   696,582 
March 31, 2015   89,125    3.91    0.8    0.41%   0%   52.45%   62,708 
April 21, 2015   3,115,000    3.85    1.4    0.68%   0%   51.54%   2,371,956 
April 21, 2015   311,500    3.85    0.8    0.68%   0%   51.54%   216,766 
May 27, 2015   1,418,750    3.76    1.4    0.46%   0%   51.74%   933,065 
May 27, 2015   141,875    3.76    0.8    0.46%   0%   51.74%   92,108 
June 30, 2015   2,035,000    3.66    1.4    0.37%   0%   52.94%   1,356,512 
June 30, 2015   203,500    3.66    0.8    0.37%   0%   52.94%   134,457 
                                    
At year end
March 31, 2016:
                                   
March 31, 2016   16,408,250    2.91    1.4    0.21%   0%   62.96%   4,585,539 
March 31, 2016   1,492,038    2.91    0.8    0.21%   0%   62.96%   550,451 
                                    
At Period End:                                   
December 31, 2016   16,408,250    2.50    1.4    0.84%   0%   69.68%   2,314,826 
December 31, 2016   1,229,993    2.50    0.8    0.84%   0%   69.68%   267,214 

 

 21 

 

 

BIONIK LABORATORIES CORP.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three and nine month periods ended December 31, 2016 and 2015

(unaudited) (Amounts expressed in U.S. Dollars)

 

11.WARRANTS (continued)

 

In addition to the forgoing, the Company also utilized a holding cost to approximate the impact of a holder of the warrant to maintain a hedging strategy in which they maintained a short position. On analysis of comparable companies and other information the Company has determined that the use of 2.25% in the simulation model is a reasonable assumption.

 

The warrant derivative liability is classified within Level 3 of the fair value hierarchy because on initial recognition and again at each reporting period, it was valued using these significant inputs and assumptions that are unobservable in the market. Changes in the values assumed and used in the simulation model can materially affect the estimate of fair value.

 

Generally, an increase in the market price of the Company’s common shares, an increase in the volatility of the Company’s common shares and an increase in the expected life would result in a directionally similar change in the estimated fair value of the warrant derivative liability. An increase in the risk free rate would result in a decrease in the fair value of the warrant derivative liability.

 

The expected life is based on the remaining contractual term of the warrants. The risk free rate was based on U.S. treasury-note yields with terms commensurate with the remaining term of the warrants. Expected volatility over the expected term of the warrants is estimated based on consideration of historical volatility and other information.

 

In addition to the assumptions above, the Company also took into consideration the probability of the Company’s participation in another round of financing, the type of such financing and the range of the stock price for the financing at that time. At each increment of the simulation, the daily volume weighted-average price was calculated. If this amount was 200% greater than the exercise price of the warrants at the time, and this threshold was maintained for 20 consecutive days, the simulation assumed the trigger of the Company’s option to redeem and the exercise of the warrants by the holder within thirty days. In the circumstance where the redemption was not triggered the warrant was valued at its discounted intrinsic value at maturity.

 

12.ROYALTY AGREEMENT

 

Prior to the acquisition of IMT in April 2012, IMT entered into a Patent License Agreement with an unrelated third party (the “Licensee”). Under the terms of the perpetual license agreement, the Company will receive royalties from the Licensee based on a licensed product sold by the Licensee. There was no royalty income during the three and nine-month periods ended December 31, 2016 and 2015 under the terms of the agreement.

 

13.LICENSING AGREEMENTS

 

The Company’s subsidiary maintains a licensing agreement with the Massachusetts Institute of Technology (“MIT”) for exclusive rights to utilize certain of MIT’s patented technology. The licensing agreement remains in effect until the expiration or abandonment of all patent rights and patent applications filed that are included under license, the last of which patent rights expires in November 2024. The agreement provides the Company with the option to sublicense the rights under the agreement. Under the terms of the agreement, as amended, royalties are payable to MIT based on 3% of certain domestic product sales and 1.5% of certain international product sales, as defined, and 50% of all sublicense income.

 

The Company recognized $2,500 and $7,500 of royalty expense under this agreement during the three and nine months ended December 31, 2016. At September 30, 2016, the Company had accrued royalty and related amounts payable to MIT of $33,369 included in accounts payable on the condensed consolidated interim balance sheets and during the quarter ended December 31, 2016, the entire balance owed was paid to MIT. One of the Company’s directors is an employee of MIT as well as the Company’s Chief Science Officer.

 

The Company maintains a second licensing agreement with the same director noted above and an unrelated third party for exclusive rights to utilize certain patented technology. The Company has exclusive rights to the patents and related applications, as defined, until expiration in May 2027. The agreement provides the Company with the option to sublicense the rights under the agreement. Under the terms of the agreement royalties are payable to the patent holders based on 1% of net sales, as defined, and 50% of all sublicense income. There have been no sales under this agreement through December 31, 2016.

 

 22 

 

 

BIONIK LABORATORIES CORP.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three and nine month periods ended December 31, 2016 and 2015

(unaudited) (Amounts expressed in U.S. Dollars)

 

14.COMMITMENTS AND CONTINGENCIES

 

Contingencies

 

From time to time, the Company may be involved in a variety of claims, suits, investigations and proceedings arising in the ordinary course of our business, collection claims, breach of contract claims, labor and employment claims, tax and other matters. Although claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, the Company believes that the resolution of current pending matters will not have a material adverse effect on its business, financial position, results of operations or cash flow. Regardless of the outcome, litigation can have an adverse impact on the Company because of legal costs, diversion of management resources and other factors.

 

15.RISK MANAGEMENT

 

The Company’s cash balances are maintained in two banks in Canada and a Canadian Bank subsidiary in the US and a US Bank. Deposits held in banks in Canada are insured up to $100,000 CAD per depositor for each bank by The Canada Deposit Insurance Corporation, a federal crown corporation. Actual balances at times may exceed these limits.

 

Interest Rate Risk

 

Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in the interest rates. The Company has minimal exposure to fluctuations in the market interest rate. In seeking to minimize the risks from interest rate fluctuations, the Company manages exposure through its normal operating and financing activities.

 

Liquidity Risk

 

Liquidity risk is the risk that the Company will incur difficulties meeting its financial obligations, as they are due. The Company’s approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due. Accounts payable and accrued liabilities are due within the current operating period.

 

The Company has funded its operations through the issuance of capital stock, convertible debt and loans in addition to grants and investment tax credits received from the Government of Canada.

 

 23 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Forward-looking Statements

 

This Quarterly Report on Form 10-Q contains statements reflecting assumptions, expectations, projections, intentions or beliefs about future events that are intended as “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements included or incorporated by reference in this Quarterly Report on Form 10-Q, other than statements of historical fact, that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements appear in a number of places, including, but not limited to in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements represent our reasonable judgment of the future based on various factors and using numerous assumptions and are subject to known and unknown risks, uncertainties and other factors that could cause our actual results and financial position to differ materially from those contemplated by the statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts, and use words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “may,” “will”, “should,” “plan,” “project” and other words of similar meaning. In particular, these include, but are not limited to, statements relating to the following:

 

·projected operating or financial results, including anticipated cash flows used in operations;

 

·expectations regarding capital expenditures; and

 

·our beliefs and assumptions relating to our liquidity position, including our ability to obtain additional financing.

 

Any or all of our forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks, uncertainties and other factors including, among others:

 

·the loss of key management personnel on whom we depend;

 

·our ability to operate our business efficiently, manage capital expenditures and costs (including general and administrative expenses) and obtain financing when required; and

 

·our expectations with respect to our acquisition activity.

 

In addition, there may be other factors that could cause our actual results to be materially different from the results referenced in the forward-looking statements, some of which are included in this Quarterly Report on Form 10-Q, including in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Many of these factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed. Our actual future results may vary materially from those expressed or implied in any forward-looking statements. All forward- looking statements contained in this Quarterly Report on Form 10-Q are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are made, and we disclaim any obligation to update any forward-looking statements to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q, except as otherwise required by applicable law.

 

This discussion and analysis should be read in conjunction with the accompanying condensed consolidated interim financial statements and related notes and the Company’s Annual Report on Form 10-KT, for the transition period ended March 31, 2016 as filed with the Securities and Exchange Commission.

 

The discussion and analysis of the financial condition and results of operations are based upon the financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of any contingent liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. On an on-going basis we review our estimates and assumptions. The estimates were based on historical experience and other assumptions that we believe to be reasonable under the circumstances. Actual results are likely to differ from those estimates under different assumptions or conditions, but we do not believe such differences will materially affect our financial position or results of operations. Bionik, Inc.’s (IMT) operations are included since its acquisition on April 21, 2016 to December 31, 2016.

 

Nature of Company

 

We are a global robotics company focused on providing rehabilitation solutions to individuals with neurological disorders, specializing in designing, developing and commercializing cost-effective physical rehabilitation technologies and assistive robotic products. We are committed to improving the quality of life for the millions of people with neurological impairment and mobility challenges, while reducing the growing financial burden to society. Our goal is to be the market leader in evidence based rehabilitative and assistive robotic technologies, allowing people to lead fuller and more independent lives.

 

Bionik Laboratories Corp. was incorporated on January 8, 2010 in the State of Colorado. At the time of our incorporation the name of our company was Strategic Dental Management Corp. On July 16, 2013, we changed our name from Strategic Dental Management Corp. to Drywave Technologies, Inc. and changed our state of incorporation from Colorado to Delaware. Effective February 13, 2015, we filed with the Secretary of State of Delaware a Certificate of Amendment to our Articles of Incorporation whereby, among other things, we changed our name to Bionik Laboratories Corp.

 

 24 

 

 

On April 21, 2016, we acquired all of the outstanding shares and, accordingly, all assets and liabilities of Interactive Motion Technologies, Inc. (IMT), a Boston, Massachusetts-based global pioneer and leader in providing effective robotic products for neurorehabilitation, pursuant to an Agreement and Plan of Merger, dated March 1, 2016, with IMT, Hermano Igo Krebs, and Bionik Mergerco Inc., a Massachusetts corporation and our wholly owned subsidiary. The merger agreement provided for the merger of Bionik Mergerco with and into IMT, with IMT surviving the merger as our wholly owned subsidiary. In return for acquiring IMT, IMT shareholders received or will receive up to an aggregate of 23,650,000 shares of our common stock. IMT’s legal name has been changed to Bionik, Inc. subsequent to April 21, 2016.

 

Through the acquisition of IMT, Bionik has added a portfolio of products focused on upper and lower extremity rehabilitation of stroke patients. We now have three products on the market and four products in varying stages of development that we are currently pursuing.

 

The InMotion ARM, InMotion ARM/HAND, and InMotion Wrist have been characterized as Class II medical devices by the U.S. Food and Drug Administration and are listed by the FDA to market and sell in the United States. In addition to these in-market products, the InMotion Anklebot is in development, and we are also developing the InMotionHome, which is an upper extremity product that allows the patient to extend their therapy for as long as needed while rehabilitating at home and is being developed on the same design platform as the InMotion clinical products. All of these products are designed to provide intelligent, patient-adaptive therapy in a manner that has been clinically verified to maximize neuro-recovery.

 

Patented technology used in the InMotion Wrist is licensed to us from the Massachusetts Institute of Technology, where Dr. Hermano Igo Krebs, our Chief Science Officer, and Neville Hogan, an advisor and former director of IMT, are professors.

 

Our products have been tested in over 240 locations across 20 countries, generating clinical data which management believes confirms a strong foundation for commercialization success. In addition, IMT's manufacturing facility is compliant with ISO-13485 and FDA regulations.

 

In addition, we are developing for commercialization the ARKE lower body exoskeleton, as well as a new product candidate for gait assistance for rehabilitation based on a design being developed by Dr. Krebs, which we expect to further advance in 2017 assuming resources are available. We plan to develop other biomechatronic solutions through internal research and development and we may further augment our product portfolio through strategic and accretive acquisition opportunities in the future.

 

We also have two earlier stage development technologies: APOLLO, an intelligent prosthetic knee; and Chronos, a cloud-based intelligent patient queuing system, which we have put on hold as we do not have the financial capability or personnel to develop these products now that our business model has changed to include the InMotion products – both existing and in development.

 

We currently hold an intellectual property portfolio that includes 5 U.S. and international patents pending, 13 U.S. provisional patents, and other patents under development. The provisional patents may not be filed as full patents and new provisional patents may be filed as the technology evolves or changes. Additionally, as a result of our acquisition of IMT, we hold exclusive licenses to three additional patents.

 

We are focused on bringing new products to market and expanding our global footprint to drive future revenue growth, including by expecting our advanced InMotion AnkleBot™ to be commercially available in the first calendar quarter of 2018, launching the next generation upper body commercial product line planned in the second calendar quarter of 2017, and negotiating with a Tier-1 ODM to optimize manufacturing and distribute products in Asian markets. We are also evaluating multiple financing options, including strategic partnerships, that are in the best interest of the Company and its shareholders in the near and long term to continue our business operations.

 

The Acquisition Transaction

 

On February 26, 2015, we entered into an Investment Agreement with Bionik Acquisition Inc. (the “Investment Agreement”), a company existing under the laws of Canada, and our wholly owned subsidiary (“Acquireco”), and Bionik Laboratories, Inc. (“Bionik Canada”), a company incorporated on March 24, 2011 under the Canada Business Corporations Act, whereby we acquired 100 Class 1 common shares of Bionik Canada representing 100% of the outstanding Class 1 common shares of Bionik Canada, taking into account the Exchangeable Share Transaction (as defined below) (the “Acquisition Transaction”). After giving effect to the Acquisition Transaction, we commenced operations through Bionik Canada.

 

Immediately prior to the closing of the Acquisition Transaction and the First Closing (as defined below), we transferred all of the business, properties, assets, operations and goodwill of the Company (other than cash and cash equivalents), and liabilities as of March 6, 2013, to our then-existing wholly owned subsidiary, Strategic Dental Alliance, Inc., a Colorado corporation (“Strategic Dental Alliance”), and then transferred all of the capital stock of Strategic Dental Alliance to Brian E. Ray, a former officer and existing director (through March 20, 2015) and Jon Lundgreen, a former officer and director, pursuant to a Spin- Off Agreement (the “Spin-Off Agreement”). Also as of immediately prior to the closing of the Acquisition Transaction and the First Closing, we entered into an Assignment and Assumption Agreement with Tungsten 74 LLC, pursuant to which Tungsten 74 LLC assumed all of our remaining liabilities through the closing of the Acquisition Transaction (the “Assignment and Assumption Agreement”). Accordingly, as of the closing of the Acquisition Transaction and the First Closing, we had no assets or liabilities.

 

As a condition of the closing of the Acquisition Transaction, Bionik Canada created a new class of exchangeable shares (the “Exchangeable Shares”), which were issued to the existing common shareholders of Bionik Canada in exchange for all of their outstanding common shares, all of which were cancelled (the “Exchangeable Share Transaction”).

 

Pursuant to the rights and privileges of the Exchangeable Shares, the holders of such Exchangeable Shares maintain the right to (i) receive dividends equal to, and paid concurrently with, dividends paid by the Company to the holders of Common Stock; (ii) vote, through the Trustee’s voting of the Special Voting Preferred Stock (as defined herein) on all matters that the holders of Common Stock are entitled to vote upon; and (iii) receive shares of Common Stock upon the liquidation or insolvency of the Company upon the redemption of such Exchangeable Shares by Acquireco.

 

 25 

 

 

As part of the Exchangeable Share Transaction, we entered into the following agreements, each dated February 26, 2015:

 

·Voting and Exchange Trust Agreement (the “Trust Agreement”) with Bionik Canada and Computershare Trust Company of Canada (the “Trustee”); and

 

·Support Agreement (the “Support Agreement”) with Acquireco and Bionik Canada

 

Pursuant to the terms of the Trust Agreement, the parties created a trust for the benefit of its beneficiaries, which are the holders of the Exchangeable Shares, enabling the Trustee to exercise the voting rights of such holders until such time as they choose to redeem their Exchangeable Shares for shares of the Common Stock of the Company, and allowing the Trustee to hold certain exchange rights in respect of the Exchangeable Shares.

 

As a condition of the Trust Agreement and prior to the execution thereof, we filed a Certificate of Designation with the Delaware Secretary of State, effective February 20, 2015, designating a class of our preferred shares as The Special Voting Preferred Stock (the “Special Voting Preferred Stock”) and issued one share of the Special Voting Preferred Stock to the Trustee.

 

The Special Voting Preferred Stock entitles the Trustee to exercise the number of votes equal to the number of Exchangeable Shares outstanding on a one-for-one basis during the term of the Trust Agreement. The Trust Agreement further sets out the terms and conditions under which holders of the Exchangeable Shares are entitled to instruct the Trustee as to how to vote during any stockholder meetings of our company.

 

Pursuant to the terms of the Trust Agreement, we granted the Trustee the right to require our Company to purchase the Exchangeable Shares from any beneficiary upon the occurrence of certain events including in the event that we are bankrupt, insolvent or our business is wound up. The Trust Agreement continues to remain in force until the earliest of the following events: (i) no outstanding Exchangeable Shares are held by any beneficiary under the Trust Agreement; and (ii) each of Bionik Canada and us elects to terminate the Trust Agreement in writing and the termination is approved by the beneficiaries.

 

Pursuant to the terms of the Support Agreement, we agreed to certain covenants while the Exchangeable Shares were outstanding, including: (i) not to declare or pay any dividends on our common stock unless simultaneously declaring the equivalent dividend for the holders of the Exchangeable Shares, (ii) advising Bionik Canada in advance of any dividend declaration by our company, (iii) ensure that the record date for any dividend or other distribution declared on the shares of the Company is not less than seven days after the declaration date of such dividend or other distribution; (iv) taking all actions reasonably necessary to enable Bionik Canada to pay and otherwise perform its obligations with respect to the issued and outstanding Exchangeable Shares, (iv) to ensure that shares of the Company are delivered to holders of Exchangeable Shares upon exercise of certain redemption rights set out in the agreement and in the rights and restrictions of the Exchangeable Shares, and (v) reserving for issuance and keeping available from our authorized common stock such number of shares as may be equal to: (A) the number of Exchangeable Shares issued and outstanding from time to time; and (B) the number of Exchangeable Shares issuable upon the exercise of all rights to acquire Exchangeable Shares from time to time.

 

The Support Agreement also outlines certain restrictions on our ability to issue any dividends, rights, options or warrants to all or substantially all of our stockholders during the term of the agreement unless the economic equivalent is provided to the holders of Exchangeable Shares. The Support Agreement is governed by the laws of the Province of Ontario.

 

Concurrently with the closing of the Acquisition Transaction and in contemplation of the Acquisition Transaction, we sold 7,735,750 units (the “Units”) for gross proceeds of $6,188,600 (including $500,000 of outstanding bridge loans converted into Units at the offering price) at a purchase price of $0.80 per Unit (the “Purchase Price”) in a private placement offering (the “Offering”). Each Unit consists of one share of common stock, par value $0.001 per share (the “Common Stock”) and a four-year warrant (the “Warrant”) to purchase one share of Common Stock at an initial exercise price of $1.40 per share (the “Warrant Shares”). We incurred share issued costs related to this transaction of $848,822.

 

The Offering was being offered with a minimum offering amount of $6,000,000 (the “Minimum Offering Amount”) and up to a maximum offering amount of $12,800,000 (subject to a $2,600,000 overallotment option). Once the Minimum Offering amount was reached and held in escrow and other conditions to closing were satisfied (including the simultaneous closing of the Acquisition Transaction), the Company and the placement agent were able to conduct a first closing (the “First Closing”). As a result of the Offering, after payment of placement agent fees and expenses but before the payment of other offering expenses such as legal and accounting expenses, we received net proceeds of approximately $5,339,778 at the First Closing, including the $500,000 in bridge loans we previously received that were taken into account as part of the Minimum Offering Amount. In addition, the placement agent was granted 10% warrant coverage for all Units sold in the Offering, which are exercisable at $0.80 per share for a period of 4 years.

 

As of the Acquisition Transaction and the First Closing, an aggregate of 90,575,126 shares of our Common Stock were deemed cancelled, of which 90,207,241 were held by the former Chief Executive Officer of Drywave.

 

Immediately following the Acquisition Transaction, the Exchangeable Share Transaction and the First Closing, there were 63,735,813 shares of our common stock and equivalents issued and outstanding of which 6,000,063 were held by existing stockholders, 7,735,750 were held by the investors in the Offering and Bionik Canada shareholders held an equivalent of 50,000,000 shares of our common stock through their ownership of 100% of the Exchangeable Shares.

 

From April 21, to June 30, 2015, we sold to accredited investors 6,568,750 Units for gross proceeds of $5,255,000. After payment of placement agent fees and expenses but before payment of offering expenses such as legal and accounting we received net proceeds of $4,556,818. Through the final closing of the Offering on June 30, 2015, we raised in the Offering aggregate gross proceeds of $13,126,600.

 

 26 

 

 

Significant Accounting Policies and Estimates

 

The discussion and analysis of the financial condition and results of operations are based upon the condensed consolidated interim financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of any contingent liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. On an on-going basis we review our estimates and assumptions. The estimates were based on historical experience and other assumptions that we believe to be reasonable under the circumstances. Actual results are likely to differ from those estimates under different assumptions or conditions, but we do not believe such differences will materially affect our financial position or results of operations.

 

Results of Operations

 

From the inception of Bionik Canada on March 24, 2011 through to December 31, 2016, we have generated a deficit of $14,056,624.

 

The Company expects to incur additional operating losses during the fiscal year ending March 31, 2017 and beyond, principally as a result of our continuing research and development, sales and marketing expenses and general and administrative costs associated with being a public company.

 

Our results of operations are presented for the three and nine months ended December 31, 2016 with comparatives for the three and nine months ended December 31, 2015. The Company changed its fiscal year to March 31, effective after the Company’s previous fiscal year ended December 31, 2015 and accordingly this report relates to the second quarter of the fiscal year ending March 31, 2017.

 

Three and Nine Months Ended December 31, 2016 Compared to the Three and Nine Months ended December 31, 2015.

 

Sales and Cost of Sales

 

The Company recorded revenues of $372,426 and $553,900 for the three and nine months ended December 31, 2016 compared to $Nil and $Nil for the three and nine months ended December 31, 2015. The 2015 revenues of IMT were not consolidated in to the prior year’s results as this was prior to the IMT acquisition. IMT unaudited revenues were $987,494 and $1,800,437 for the three and full nine months ended December 31, 2015.

 

In 2015, the acquired company was under-funded and had no commercial sales team, which significantly impacted 2016 revenues. The Company hired a Chief Commercialization Officer in August 2016 to build out the sales and marketing team, and has seen positive initial results of these efforts, which we expect to accelerate as the Company continues to invest in commercialization efforts. Based on the strong clinical data, new sales and marketing efforts, an expanded product range as well as expanding the Company’s sales efforts geographically, the Company expects revenues to grow significantly from 2016 levels in 2017 and beyond.

 

Cost of sales was $334,786 and $405,680 for the three and nine months ended December 31, 2016 ($Nil and $Nil for the three and nine months ended December 31, 2015). The gross margin of 10% in the quarter and 27% for the nine months has been impacted by a write off in the quarter of $43,009 of inventories not expected to be used due to the introduction of a new version of the InMotion equipment expected in 2017 and $129,416 resulting from an internal sample count of inventories at December 31, 2016. If the provision recorded for inventory was excluded, then the gross margins would be 56% for the three month period ended December 31, 2016 and 58% for the nine month period ended December 31, 2016.

 

Gross margin of 10% and 27% for the three and nine months ended December 31, 2016 ($Nil and $Nil) and for the three and nine months ended December 31, 2015 reflect the additional write-off noted above during the three months ended December 31, 2016. Cost of goods also includes related employee allocated costs. We expect that margins will improve with higher sales in 2017 and beyond.

 

Operating Expenses

 

Total operating expenses for the three and nine months ended December 31, 2016 were $1,609,954 and $5,450,290 compared to $1,066,482 and $4,675,810 for the three and nine months ended December 31, 2015 as further detailed below.

 

Sales and marketing expenses were $377,046 and $646,509 for the three and nine month periods ended December 31, 2016 ($Nil and $Nil for the three and nine month periods ended December 31, 2015). Sales and marketing expenses are related to the InMotion product acquired in the IMT acquisition. For the period ended December 31, 2015, the Company had no products in the market. The acquisition of IMT improved market products, resulting in sales and marketing expenses. In addition, since August 2016, the sales and marketing team has been expanded to focus on existing products and increasing revenues.

 

Research and development expenses were $571,671 and $1,803,234 for the three and nine months ended December 31, 2016, compared to expenses of $593,686 and $1,971,809 for the three and nine months ended December 31, 2015. The decrease for the nine months relates primarily to less prototyping of products nearing completion of engineering and a decrease due to a senior executive who left the Company, being partially offset by higher expenses resulting from the IMT becoming part of the Company.

 

For the three and nine months ended December 31, 2016, the Company incurred general and administrative expenses of $409,669 and $2,291,136 compared to general and administrative expenses of $438,628 and $1,313,071 for the three and nine months ended December 31, 2015. These expenses realized a slight decrease in the three month period; however, the increase in these expenses over the nine-month period is primarily due to increased legal and accounting costs, the costs of being a public company, the added costs of the IMT acquisition and additional administration costs resulting from IMT becoming a part of the Company.

 

 27 

 

 

For the three and nine months ended December 31, 2016, the Company recorded $227,540 and $651,630 in share-based compensation expense compared to $13,291 and $1,337,573 in the three and nine months ended December 31, 2015. The decrease in stock compensation expense relates to fewer stock options granted by the Company in this period over the corresponding prior nine-month period and fewer shares issued to consultants for services provided. Options previously granted by IMT prior to the Acquisition Transaction were revalued on its completion of the transaction and new options granted and options vesting during the quarter and the year to date resulted in the current expense.

 

Other Expenses

 

For the three and nine months ended December 31, 2016, the Company incurred interest expense of $13,808 and $23,839 compared to interest expense of $Nil and $Nil for the three months and nine months ended December 31, 2015. The changes in interest expenses relates to the Company having more interest bearing debt during the period as a result of the IMT acquisition.

 

During the three and nine month periods ended December 31, 2016, the Company recorded a gain of $771,341 and $2,510,388 on re-measurement to fair value at period end December 31, 2016 (gain of $2,457,778 and $6,871,597 for the three and nine months ended December 31, 2015) which was recorded within the Company’s consolidated statements of operations and comprehensive loss and represents a non-cash item. Simultaneously with any reduction to the exercise price, the number of shares of common stock that may be purchased upon exercise of each of these warrants shall be increased based on a pre-defined formula.

 

The Company’s outstanding warrants include price protection provisions that allow for a reduction in the exercise price of the warrants in the event the Company subsequently issues certain common stock or options, rights, warrants or securities convertible or exchangeable for shares of common stock at a price lower than the exercise price of the warrants

 

Other Income

 

For the three and nine months ended December 31, 2016, the Company had other income of $(4,363) and $(410,877) compared to other income of $(5,566) and $(28,578) for the three and nine months ended December 31, 2015. The increase is other income in the nine months ended December 31, 2016 was due to the receipt of the Company’s final scientific research credit from the Canadian government which related to a claim when the Company was a private company as well as the sale of redundant equipment and interest income. In 2015, other income was from interest income only.

 

Gain and losses included in other comprehensive income

 

Effective April 1, 2015, the Company changed the functional currency of its wholly owned subsidiaries, Bionik Acquisition Inc. and Bionik Canada from the Canadian dollar to the U.S. dollar. This reflects the fact that an economic environment influences the majority of the Company’s business denominated in U.S. currency, and the Company sells its product and service revenues in U.S. dollars.

 

Comprehensive Loss

 

Comprehensive loss for the three months ended December 31, 2016 amounted to $(810,418) or $(0.01) per share and the comprehensive loss for the nine months ended December 31, 2016 was $(2,404,644) resulting in a loss per share of $(0.03) compared to comprehensive income of $1,212,737 for the three months ended December 31, 2015, resulting in income per share of $0.02, and for the nine months ended December 31, 2015 income of $2,040,240 which resulted in income per share of $0.03.

 

The comprehensive loss for the three months ended December 31, 2016 compared to the three months ended December 31, 2015 is impacted by change in fair value of warrant derivative liability resulting in a non-cash gain of $771,341 in the three-month period ended December 31, 2016 (December 31, 2015 - $2,457,778).

 

Liquidity and Capital Resources

 

IMT generated approximately $2,000,000 of revenue in 2015, however since its acquisition on April 21, 2016, we have reported revenue of $553,900 for the period of April 21, 2016 to December 31, 2016. The capital budget approval process for InMotion products has a 12 to 18 months sale cycle. Underinvestment in the IMT sales and marketing resources in 2015 negatively impacted our 2016 revenues. In August 2016, we began rebuilding the sales and marketing infrastructure, which we expect to significantly increase revenues over the course of 2017 and future years. We can give no assurance that we will generate similar or greater revenues for the year ending March 31, 2017, when compared to 2015.

 

We have funded operations through the issuance of capital stock, loans, grants and investment tax credits received from the Government of Canada. We raised in our 2015 private offering aggregate gross proceeds of $13,126,600, which resulted in net proceeds after costs of $11,341,397. At December 31, 2016, we had cash and cash equivalents of $580,952.

 

Additionally, as a result of the acquisition of IMT, the Company indirectly assumed an aggregate of approximately $1.26 million of debts and other liabilities of IMT, based on the internal, unaudited financial information of IMT, of which approximately 50% - mostly trade payables - have been repaid at December 31, 2016. The remaining debt assumed is due at March 1, 2017 and December 31, 2017. The Company hopes to renegotiate the $200,000 promissory note payable and interest before March 1, 2017.

 

In late December 31, 2016, certain of the Company’s shareholders agreed to loan the company $1,500,000, $500,000 in December, $500,000 in January 2017 and $500,000 in February 2017, of which $483,333 of the initial $500,000 loan was received on December 31, 2016. These loans are convertible under certain circumstances and bear interest at 6%. These loans are due to be converted or repaid by March 31, 2017.

 

 28 

 

 

The Company has signed with one finance company to assist with the capital sales process, which we hope will accelerate cash payments from sales in the future.

 

There is however no certainty that we will be successful in generating sufficient cash flow from operations or achieving and maintaining profitable operations in the future to enable us to meet our obligations as they come due and consequently continue as a going concern.

 

The Company will require additional funds to further develop our expanded business plan, including the anticipated commercialization of the ARKE, the marketing of our newly acquired InMotion products and the development of our development product pipeline.

 

The Company will require additional financing this year to fund our operations and we are currently working on securing this funding through corporate collaborations, public or private equity offerings or debt financings. Sales of additional equity securities would result in the dilution of the interests of existing stockholders. There can be no assurance that financing will be available when required. In the event that the necessary additional financing is not obtained, we would reduce our discretionary overhead costs substantially, or otherwise curtail operations.

 

These conditions raise substantial doubt about our ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on recoverability and reclassification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

 

The Company also need additional funds to respond to business opportunities including potential acquisitions of complementary technologies or business, protect our intellectual property, develop new lines of business and enhance our operating infrastructure. While we may need to seek additional funding for any such purposes, we may not be able to obtain financing on acceptable terms, or at all. In addition, the terms of our financings may be dilutive to, or otherwise adversely affect, holders of our common stock. We may seek additional funds through arrangements with collaborators or other third parties. We may not be able to negotiate any such arrangements on acceptable terms, if at all. If we are unable to obtain additional funding on a timely basis, we may be required to curtail or terminate some or all of our product lines.

 

As we proceed with the ARKE product development, the marketing of the three commercial products of IMT and the development of other development-stage products, we have devoted and expect to continue to devote significant resources in the areas of capital expenditures and research and development costs and operations, marketing, clinical trials and sales expenditures, all subject to available cash.

 

Net Cash Used in Operating Activities

 

During the nine months ended December 31, 2016, the Company used cash in operating activities of $5,540,946 compared to $3,717,574 for the nine months ended December 31, 2015. The increased use of cash is mainly attributable to the larger loss in the nine months ended December 31, 2016 than the nine months ended December 31, 2015, due to higher general and administrative costs and the costs of becoming a public company and $2,510,388 of change in the fair value of the warrant derivative liability compared to $6,871,597 in the nine months ended December 31, 2015. The change in fair value of warrant derivative liability is a non-cash item.

 

Net Cash Used in Investing Activities

 

During the nine months ended December 31, 2016, net cash used in investing activities was $9,827 and for the nine months ended December 31, 2015, net cash used in investing activities of $347,270. The decrease in investing activities in 2016 is a result of there being no loans made as there was in 2015 and minimal cash additions to equipment.

 

Net Cash Provided by Financing Activities

 

Net cash provided by financing activities was $749,968 for the nine months ended December 31, 2016 compared to cash provided by financing activities of $4,556,818 for the nine months ended December 31, 2015. The decrease is due to the Company completing an Offering in 2015, and having raised no capital during 2016. However, the balance in 2016 reflects the cash remaining from a $900,000 advance sent to IMT immediately before the acquisition close of which $266,635 remained on hand on April 21, 2016, as well as convertible loans received from shareholders and the convertible loans received from shareholders in December 2016.

 

 29 

 

 

Recent Issued Accounting Pronouncements

 

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2017. Early adoption is not permitted. The impact on the consolidated financial statements of adopting ASU 2014-09 will be assessed by management.

 

In August 2014, the FASB issued a new financial accounting standard on going concern, ASU No. 2014-15, “Presentation of Financial Statements – Going Concern (Sub-Topic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The standard provides guidance about management’s responsibility to evaluate whether there is a substantial doubt about the organization’s ability to continue as a going concern. The amendments in this Update apply to all companies. They become effective in the annual period ending after December 15, 2016, with early application permitted. The impact on the consolidated financial statements of adopting ASU 2014-15 will be assessed by management.

 

In September 2015, the FASB issued ASU No. 2015-16, “Simplifying the Accounting for Measurement-Period Adjustments,” which illustrates certain guidance governing adjustments to the provisional amounts recognized at the acquisition date with a corresponding adjustment to goodwill. Such adjustments are required when new information is obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement amounts initially recognized or would have resulted in the recognition of additional assets and liabilities. ASU No. 2015-16 eliminates the requirement to retrospectively account for such adjustments. ASU No. 2015-16 is effective for the fiscal year commencing on January 1, 2016. The Company has adopted this ASU No. 2015-16 as at and for the three and twelve month periods ended March 31, 2016. There was no material effect on the consolidated financial position or the consolidated results of operations and comprehensive loss.

 

In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes,” which requires that deferred tax liabilities and assets be classified on our Consolidated Balance Sheets as noncurrent based on an analysis of each taxpaying component within a jurisdiction. ASU No. 2015-17 is effective for the fiscal year commencing on January 1, 2017. The Company does not anticipate that the adoption of ASU No. 2015-17 will have a material effect on the consolidated financial position or the consolidated results of operations.

 

In February 2016, the FASB issued ASU 2016-02, Leases. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company is still assessing the impact that the adoption of ASI 2016-02 will have on the consolidated financial position and the consolidated results of operations.

 

In March 2016, the FASB issued ASU 2016-09, "Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting". Several aspects of the accounting for share-based payment award transaction are simplified, including (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company is still assessing the impact that the adoption of ASI 2016-09 will have on the consolidated financial position and the consolidated results of operations.

 

In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. This ASU provides eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for the fiscal year commencing after November 1, 2018. The Company is still assessing the impact that the adoption of ASI 2016-15 will have on the consolidated statement of cash flows.

 

In January 2017, the FASB issued ASU 2017-01, “Business Combinations: Clarifying the definition of a Business” which amends the current definition of a business. Under ASU 2017-01, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contributes to the ability to create outputs. ASU 2017-01 further states that when substantially all of the fair value of gross assets acquitted is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. The new guidance also narrows the definition of the term “outputs” to be consistent with how it is described in Topic 606, Revenue from Contracts with Customers. The changes to the definition of a business will likely result in more acquisitions being accounted for as asset acquisitions. ASU 2017-01 is effective for acquisitions commencing on or after June 30, 2019, with early adoption permitted. Adoption of this guidance will be applied prospectively on or after the effective date.

 

In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other” ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test, which required a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. ASU 2017-04 is effective for financial statements issued for fiscal years, and interim periods beginning after December 15, 2019.

 

 30 

 

 

 

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying condensed consolidated interim financial statements.

 

Off Balance Sheet Arrangements

 

We have no off-balance sheet transactions.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

Not applicable for smaller reporting companies.

 

Item 4. Controls and Procedures

 

During the three and nine months ended December 31, 2016, there were no changes in our internal controls over financial reporting (as defined in Rule 13a- 15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Evaluation of Disclosure Controls and Procedures

 

We maintain “disclosure controls and procedures” as such term is defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

 

As of the end of the period covered by this Quarterly Report, we carried out an evaluation, under the supervision and with the participation of our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rules 13a-15(b) and 15d-15(b). Based upon this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures as of the end of the period covered by this Quarterly Report were ineffective due to a lack of segregation of duties as well as lack of administrative and financial personnel and related resources.

 

 31 

 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings

 

None

 

Item 1A. Risk Factors

 

Not applicable for smaller reporting companies

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None

 

Item 3. Defaults Upon Senior Securities.

 

None

 

Item 4. Mine Safety Disclosures

 

Not applicable

 

Item 5. Other Information

 

None

 

Item 6. Exhibits

 

Exhibit 31.1 - Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 31.2 - Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 32.1 - Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 32.2 - Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

Exhibit 101.INS - XBRL Instance Document

Exhibit 101.SCH - XBRL Taxonomy Extension Schema Document

Exhibit 101.CAL - XBRL Taxonomy Extension Calculation Linkbase Document

Exhibit 101.DEF - XBRL Taxonomy Extension Definition Linkbase Document

Exhibit 101.LAB - XBRL Taxonomy Extension Label Linkbase Document

Exhibit 101.PRE - XBRL Taxonomy Extension Presentation Linkbase Document

 

 32 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Dated: February 14, 2017    
     
  BIONIK LABORATORIES CORP.
     
  By: /s/ Peter Bloch
  Name:    Peter Bloch
    Chief Executive Officer
    (Principal Executive Officer)
     
  By: /s/ Leslie Markow
  Name: Leslie Markow
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

 33